Dejana Vidojevic1, Stefan Seman2, Ratko Lasica3, Milorad Tesic3, Marija Saric Matutinovic1, Snezana Jovicic1, Svetlana Ignjatovic1, Ross Arena4, Svetozar Damjanovic5, Dejana Popovic6,7. 1. Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, Belgrade, 11000, Serbia. 2. Faculty of Sport and Physical Education, Balgoja Parovica 156, Belgrade, 11000, Serbia. 3. Division of Cardiology, University of Belgrade, Visegradska 26, Belgrade, 11000, Serbia. 4. Department of Physical Therapy, College of Applied Health Sciences, University of Illinois at Chicago, 1919 W. Taylor St, Chicago, IL, 60612, USA. 5. Division of Endocrinology, Clinical Center of Serbia, University of Belgrade, Dr Subotica 13, Belgrade, 11000, Serbia. 6. Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, Belgrade, 11000, Serbia. dejanapopovic@yahoo.co.uk. 7. Division of Cardiology, University of Belgrade, Visegradska 26, Belgrade, 11000, Serbia. dejanapopovic@yahoo.co.uk.
Abstract
PURPOSE: Alpha-melanocyte-stimulating hormone (alpha-MSH) has proven cardiovascular effects and plays a significant role as an endogenous countermeasure to ischemia-reperfusion injury. The aim of the current study was to examine the response of alpha-MSH during exercise in patients diagnosed with coronary artery disease (CAD) and evaluate its value in the assessment of severity and prognosis. METHODS: Forty subjects with documented CAD (i.e., lesions on coronary angiography ≥ 50%) were included. Cardiopulmonary exercise testing (CPET) on a treadmill (TM) and recumbent ergometer (RE) were performed on two visits, 2-4 days apart, during 2 months of coronary angiography; subsequently, the subjects were followed up for 32 ± 10 months. At rest, at peak CPET, and after 3 min of recovery, plasma levels of alpha-MSH were measured by enzyme-linked immunosorbent assay technique. RESULTS: Mean ejection fraction was 56.7 ± 9.6%. Alpha-MSH similarly increased from rest to peak CPET on both modalities. There were no significant differences in alpha-MSH values during testing in patients with 1,2- and 3-vesel CAD, nor in patients with a SYNTAX score </≥ 23 (p > 0.05). Among CPET and hormonal parameters, ∆alpha-MSH recovery/peak during RE CPET was the best predictor of cardiac event occurrence (chi-square 6.67, HR = 0.51, CI = 0.25-1.02, p = 0.010). CONCLUSION: ∆alpha-MSH recovery/peak during RE CPET has predictive value for CAD prognosis, demonstrating involvement of alpha-MSH in CAD and a link between stress hormones and cardiac events.
PURPOSE: Alpha-melanocyte-stimulating hormone (alpha-MSH) has proven cardiovascular effects and plays a significant role as an endogenous countermeasure to ischemia-reperfusion injury. The aim of the current study was to examine the response of alpha-MSH during exercise in patients diagnosed with coronary artery disease (CAD) and evaluate its value in the assessment of severity and prognosis. METHODS: Forty subjects with documented CAD (i.e., lesions on coronary angiography ≥ 50%) were included. Cardiopulmonary exercise testing (CPET) on a treadmill (TM) and recumbent ergometer (RE) were performed on two visits, 2-4 days apart, during 2 months of coronary angiography; subsequently, the subjects were followed up for 32 ± 10 months. At rest, at peak CPET, and after 3 min of recovery, plasma levels of alpha-MSH were measured by enzyme-linked immunosorbent assay technique. RESULTS: Mean ejection fraction was 56.7 ± 9.6%. Alpha-MSH similarly increased from rest to peak CPET on both modalities. There were no significant differences in alpha-MSH values during testing in patients with 1,2- and 3-vesel CAD, nor in patients with a SYNTAX score </≥ 23 (p > 0.05). Among CPET and hormonal parameters, ∆alpha-MSH recovery/peak during RE CPET was the best predictor of cardiac event occurrence (chi-square 6.67, HR = 0.51, CI = 0.25-1.02, p = 0.010). CONCLUSION: ∆alpha-MSH recovery/peak during RE CPET has predictive value for CAD prognosis, demonstrating involvement of alpha-MSH in CAD and a link between stress hormones and cardiac events.
Authors: P J Scanlon; D P Faxon; A M Audet; B Carabello; G J Dehmer; K A Eagle; R D Legako; D F Leon; J A Murray; S E Nissen; C J Pepine; R M Watson; J L Ritchie; R J Gibbons; M D Cheitlin; T J Gardner; A Garson; R O Russell; T J Ryan; S C Smith Journal: J Am Coll Cardiol Date: 1999-05 Impact factor: 24.094
Authors: Gualtiero Colombo; Stefano Gatti; Flavia Turcatti; Andrea Sordi; Luigi R Fassati; Ferruccio Bonino; James M Lipton; Anna Catania Journal: J Immunol Date: 2005-09-01 Impact factor: 5.422
Authors: Georgios Sianos; Marie-Angèle Morel; Arie Pieter Kappetein; Marie-Claude Morice; Antonio Colombo; Keith Dawkins; Marcel van den Brand; Nic Van Dyck; Mary E Russell; Friedrich W Mohr; Patrick W Serruys Journal: EuroIntervention Date: 2005-08 Impact factor: 6.534
Authors: Stephen J Getting; Clara Di Filippo; Helen C Christian; Connie W Lam; Francesco Rossi; Michele D'Amico; Mauro Perretti Journal: J Leukoc Biol Date: 2004-07-26 Impact factor: 4.962